PTGX Protagonist Therapeutics


Data from SEC filings
Employee count

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

At the Protagonist Therapeutics, Inc. (the “Company”) 2021 Annual Meeting of Stockholders (the “Annual Meeting”) held on May 27, 2021, the stockholders voted on the two proposals listed below. The proposals are described in detail in the Company’s definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on April 14, 2021. The results of the matters voted upon at the meeting were:

Proposal 1 — To elect the three Class II directors named below to serve until the 2024 Annual Meeting of Stockholders. Each of the three named nominees was so elected, with the votes thereon at the Annual Meeting as follows:

Final Voting Results
NomineesForWithheldBroker Non-Votes
Sarah A. O’Dowd38,323,022306,1012,984,809
William D. Waddill34,282,2864,346,8372,984,809
Lewis T. “Rusty” Williams, M.D., Ph.D.34,296,5204,332,6032,984,809

Proposal 2 — To ratify the selection by the Audit Committee of the Board of Directors of the Company of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. This proposal was approved by the requisite vote, with the votes thereon at the Annual Meeting as follows:

Final Voting Results
ForAgainstAbstainBroker Non-Votes

No other matters were submitted for stockholder action.